Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.79 |
| ▸ | LMNA | P02545 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | RAD52 | P43351 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.71 |
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20412084 | 1.00 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL30703686 | 0.99 | FPR2 (0.81) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412094 | 0.99 | FPR2 (0.81) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL31673755 | 0.98 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412107 | 0.98 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412115 | 0.97 | FPR2 (0.81) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Cyclophenazine SCHEMBL351628 | 0.92 | FPR2 (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Cyclophenazine SCHEMBL29710907 | 0.92 | FPR2 (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20427426 | 0.91 | FPR2 (0.72) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Cyclophenazine SCHEMBL122920 | 0.91 | LMNA (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | claimed |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP188, NUP50 | FPR2 4728/4885LMNA 171/4885MAPT 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.